```
     FILE 'CAPLUS' ENTERED AT 08:42:55 ON 13 JUN 2000
L1             1 S WO9837877/PN
               SELECT
L1 1 RN

     FILE 'REGISTRY' ENTERED AT 08:43:33 ON 13 JUN 2000
L2           199 S E1-E199
L3             0 S L2 AND ?PYRAN?
L4             0 S L2 AND TETRAHYDROPYRAN?
L5           200 S E200-E399
L6             3 S L5 AND (PYRAN? OR TETRHYDROPYRAN?)
L7             3 S L5 AND (PYRAN? OR TETRAHYDROPYRAN?)
L8           235 S E400-E634
L9             0 S L8 AND (PYRAN? OR TETRAHYDROPYRAN?)

     FILE 'REGISTRY' ENTERED AT 08:52:31 ON 13 JUN 2000
L10            STRUC
L11           27 S L10
L12           513 S L10 FUL
L13           27 S L12

     FILE 'CAPLUS' ENTERED AT 08:55:09 ON 13 JUN 2000
L14            3 S L12

     FILE 'CAPLUS' ENTERED AT 09:00:22 ON 13 JUN 2000
```

```
L2          199 (212766-32-0/BI OR 212767-07-2/BI OR 212767-08-3/BI OR
212767-16
                -3/BI OR 212767-22-1/BI OR 212767-28-7/BI OR 212767-37-8/BI OR
                212767-43-6/BI OR 212767-49-2/BI OR 212767-52-7/BI OR
212767-57-
                2/BI OR 212768-04-2/BI OR 212768-26-8/BI OR 212768-31-5/BI OR
                212768-38-2/BI OR 100-39-0/BI OR 100-51-6/BI OR 100620-68-6/BI
                OR 101-32-6/BI OR 10125-86-7/BI OR 101279-39-4/BI OR
102-47-6/BI
                 OR 102-79-4/BI OR 103-63-9/BI OR 104-82-5/BI OR 10429-82-0/BI
                OR 105-36-2/BI OR 106-53-6/BI OR 107-82-4/BI OR 110-52-1/BI OR
                111-42-2/BI OR 111-83-1/BI OR 1122-97-0/BI OR 1138-79-0/BI OR
                114331-45-2/BI OR 118486-94-5/BI OR 1200-03-9/BI OR
123-00-2/BI
                OR 123401-97-8/BI OR 134649-63-1/BI OR 134937-39-6/BI OR
141907-
                41-7/BI OR 146480-36-6/BI OR 14980-92-8/BI OR 151769-16-3/BI
OR
                16503-53-0/BI OR 165377-37-7/BI OR 1667-11-4/BI OR
166747-48-4/B
                I OR 1679-18-1/BI OR 175449-82-8/BI OR 17630-29-4/BI OR
18217-00
                -0/BI OR 18495-27-7/BI OR 20038-12-4/BI OR 206550-68-7/BI OR
                206550-70-1/BI OR 207279-39-8/BI OR 2126

=> s l2 and ?pyran?

LEFT TRUNCATION IGNORED FOR '?PYRAN?' FOR FILE 'REGISTRY'
        773527 PYRAN?
L3           0 L2 AND ?PYRAN?
Left truncation is not valid in the specified search field in the
specified file.  The term has been searched without left truncation.
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you
used a truncation symbol after a punctuation mark, the system may
interpret the truncation symbol as being at the beginning of a term.
Implied proximity is used in search fields indexed as single words,
for example, the Basic Index.

=> s l2 and tetrahydropyran?

          2702 TETRAHYDROPYRAN?
L4           0 L2 AND TETRAHYDROPYRAN?
```

```
L8          235 (212769-78-3/BI OR 212769-79-4/BI OR 212769-80-7/BI OR
212769-81
                -8/BI OR 212769-82-9/BI OR 212769-83-0/BI OR 212769-84-1/BI OR
                212769-85-2/BI OR 212769-86-3/BI OR 212769-87-4/BI OR
212769-88-
                5/BI OR 212769-89-6/BI OR 212769-90-9/BI OR 212769-91-0/BI OR
                212769-92-1/BI OR 212769-93-2/BI OR 212769-94-3/BI OR
212769-95-
                4/BI OR 212769-96-5/BI OR 212769-97-6/BI OR 212769-98-7/BI OR
                212769-99-8/BI OR 212770-00-8/BI OR 212770-01-9/BI OR
212770-02-
                0/BI OR 212770-03-1/BI OR 212770-04-2/BI OR 212770-05-3/BI OR
                212770-06-4/BI OR 212770-07-5/BI OR 212770-08-6/BI OR
212770-09-
                7/BI OR 212770-10-0/BI OR 212770-11-1/BI OR 212770-12-2/BI OR
                212770-13-3/BI OR 212770-14-4/BI OR 212770-15-5/BI OR
212770-16-
                6/BI OR 212770-17-7/BI OR 212770-18-8/BI OR 212770-19-9/BI OR
                212770-20-2/BI OR 212770-21-3/BI OR 212770-22-4/BI OR
212770-23-
                5/BI OR 212770-24-6/BI OR 212770-25-7/BI OR 212770-26-8/BI OR
                212770-27-9/BI OR 212770-29-1/BI OR 212770-30-4/BI OR
212770-31-
                5/BI OR 212770-32-6/BI OR 212770-33-7/BI O

=> s l8 and (pyran? or tetrahydropyran?)

         773527 PYRAN?
           2702 TETRAHYDROPYRAN?
L9            0 L8 AND (PYRAN? OR TETRAHYDROPYRAN?)
```

L5 200 (212767-46-9/BI OR 212767-47-0/BI OR 212767-48-1/BI OR 212767-50
-5/BI OR 212767-51-6/BI OR 212767-53-8/BI OR 212767-54-9/BI OR
212767-55-0/BI OR 212767-56-1/BI OR 212767-58-3/BI OR 212767-59-
4/BI OR 212767-60-7/BI OR 212767-61-8/BI OR 212767-62-9/BI OR
212767-63-0/BI OR 212767-64-1/BI OR 212767-65-2/BI OR 212767-66-
3/BI OR 212767-67-4/BI OR 212767-68-5/BI OR 212767-70-9/BI OR
212767-72-1/BI OR 212767-74-3/BI OR 212767-76-5/BI OR 212767-78-
7/BI OR 212767-80-1/BI OR 212767-82-3/BI OR 212767-84-5/BI OR
212767-85-6/BI OR 212767-86-7/BI OR 212767-87-8/BI OR 212767-88-
9/BI OR 212767-89-0/BI OR 212767-90-3/BI OR 212767-91-4/BI OR
212767-92-5/BI OR 212767-93-6/BI OR 212767-94-7/BI OR 212767-95-
8/BI OR 212767-96-9/BI OR 212767-97-0/BI OR 212767-98-1/BI OR
212767-99-2/BI OR 212768-00-8/BI OR 212768-01-9/BI OR 212768-02-
0/BI OR 212768-03-1/BI OR 212768-05-3/BI OR 212768-06-4/BI OR
212768-07-5/BI OR 212768-08-6/BI OR 212768-09-7/BI OR 212768-10-
0/BI OR 212768-11-1/BI OR 212768-12-2/BI O

=> s l5 and (pyran? or tetrhydropyran?)

773527 PYRAN?
0 TETRHYDROPYRAN?
L6 3 L5 AND (PYRAN? OR TETRHYDROPYRAN?)

=> s l5 and (pyran? or tetrahydropyran?)

773527 PYRAN?
2702 TETRAHYDROPYRAN?
L7 3 L5 AND (PYRAN? OR TETRAHYDROPYRAN?)

=> d scan

L7 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN **Octanamide, N-hydroxy-2-[[4-[(tetrahydro-2H-pyran-4-yl)oxy]phenyl]sulfonyl]- (9CI)**
MF C19 H29 N O6 S





AN **131:336951** CA
TI Preparation of substituted aryl hydroxamic acids as metalloproteinase inhibitors
IN Xue, Chu-Biao; Decicco, Carl P.; Wexler, Ruth R.
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958528	A1	19991118	WO 1999-US10358	19990512
	W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9940747	A1	19991129	AU 1999-40747	19990512

PRAI US 1998-85393 19980514
WO 1999-US10358 19990512
OS MARPAT 131:336951
GI For diagram(s), see printed CA Issue.
AB Aryl hydroxamic acids I [ring is a 5-8 membered ring contg. 0-2 heteroatoms selected from N, O, and S; Rb = F, Me; X = CH2CO, CH2CO2, CH2CONH, etc.; Y = OCH2O, CH2O, OCHMe, etc.; Z = CH, N; R1 = F, H, Cl, Et, etc.; R2 = F, Cl, Br, I, MeO, etc.; R3 = CHMe2, F, Cl, CF3, etc.; R4 = H; R3R4 form a 5-6 membered arom. ring contg. 0-2 heteroatoms; p = 0-2], which are useful as metalloprotease inhibitors (no data), were prepd. E.g., 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide mono(trifluoroacetate) was prepd.
RE.CNT 3
RE
(1) Ciba Geigy AG; WO 9600214 A 1996
(2) Hoffmann La Roche; EP 0780386 A 1997
(3) McDonald, J; WO 9839315 A 1998

L4 30 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 2H-Pyran-4-carboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy- (9CI)
MF C21 H26 N2 O6 S
CI COM



L4 30 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 2H-Pyran-4-carboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, mono(trifluoroacetate) (salt) (9CI)
MF C21 H26 N2 O6 S . C2 H F3 O2

CM 1



CM 2



L4 30 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI)
MF C23 H24 N2 O6 S
CI COM



L4 30 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, mono(trifluoroacetate) (salt) (9CI)
MF C23 H24 N2 O6 S . C2 H F3 O2

CM 1



L1 HAS NO ANSWERS
L1 STR



REP G1=(0-1) CH2
VAR G2=2/3/4
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 3
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

=> s l1 ful

FULL SEARCH INITIATED 10:47:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4204 TO ITERATE

100.0% PROCESSED 4204 ITERATIONS 576 ANSWERS
SEARCH TIME: 00.00.01

L3 576 SEA SSS FUL L1

=> d scan

L3 576 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 2H-Pyran-4-carboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]thio]methyl]tetrahydro-N-hydroxy- (9CI)
MF C21 H26 N2 O4 S


Me
N
O
O—CH2
Me
CH2—S
HO—NH—C
O

L4 HAS NO ANSWERS
L4 STR



REP G1=(0-1) CH2
VAR G2=2/3/4
VAR G3=2/1/6
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 3
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> search l4

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset

ENTER SUBSET L# OR (END):l3

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful

FULL SUBSET SEARCH INITIATED 10:50:57 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 564 TO ITERATE

100.0% PROCESSED 564 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L5 0 SEA SUB=L3 SSS FUL L4




```
REP G1=(0-1) CH2
VAR G2=2/3/4
VAR G3=2/1/6
ENTER (DIS), GRA, NOD, BON OR ?:end

L6   STRUCTURE CREATED

=> s l6

SAMPLE SEARCH INITIATED 10:52:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     42 TO ITERATE

100.0% PROCESSED      42 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          452 TO     1228
PROJECTED ANSWERS:               0 TO        0

L7            0 SEA SSS SAM L6

=> search l6

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset

ENTER SUBSET L# OR (END):l3

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful

FULL SUBSET SEARCH INITIATED 10:53:22 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    520 TO ITERATE

100.0% PROCESSED     520 ITERATIONS                               0 ANSWERS
SEARCH TIME: 00.00.01

L8            0 SEA SUB=L3 SSS FUL L6
```

```
=> s l3

L9          30 L3

=> s l9 and metallo?

         77253 METALLO?
L10         20 L9 AND METALLO?

=> s l10 and (sulphon? or sulfon?)

           343 SULPHON?
        159641 SULFON?
L11          9 L10 AND (SULPHON? OR SULFON?)

=> d bib abs 1-9


L11  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2000 ACS
AN   2000:84604  CAPLUS
DN   132:141951
TI   Pharmaceutical compositions containing ACAT and MMP inhibitors for the
     treatment of atherosclerotic lesions
IN   Bocan, Thomas Michael Andrew
PA   Warner-Lambert Company, USA
SO   PCT Int. Appl., 222 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2000004892      A2   20000203       WO 1999-US13948  19990618
         W:  AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU,
             ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX,
             NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 1998-93639    19980721
AB   Acyl-CoA:cholesterol acyltransferase (ACAT) and matrix
     metalloproteinase (MMP) inhibitors are coadministered for the
     redn. of both the macrophage and smooth muscle cell component of
     atherosclerotic lesions, thus impairing the expansion of existing lesions
     and the development of new lesions and for the prevention of plaque
     rupture and the promotion of lesion regression in a mammal.  The direct
     antiatherosclerotic potential of the combination of ACAT inhibitor,
     [[2,4,6-tris-(1-methyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl
     sulfamic acid, and the HMG-CoA reductase inhibitor, simavastatin, in
     rabbits was studied.  A tablet contained 2-(4'-bromobiphenyl-4-
     sulfonylamino)-3-Me butyric acid 25 ACAT compd. lactose 50, corn
     starch 20, and magnesium stearate 5 mg.

L11  ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2000 ACS
AN   1999:810931  CAPLUS
```

DN 132:51446
TI Production of 3-(arylsulfur) hydroxamic acids and intermediates therefor
IN Campbell, Jeffrey Allen; Dvorak, Charles Alois; Fisher, Lawrence Emerson; McGrane, Paul Leo
PA F. Hoffmann-La Roche A.-G., Switz.
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 965592	A1	19991222	EP 1999-111308	19990610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000026401	A2	20000125	JP 1999-167596	19990615

PRAI US 1998-89778 19980618
OS MARPAT 132:51446
AB The title hydroxamic acids YCOC(R1)(R2)CH2SOnR3 in which Y is hydroxy or X1ONX2, where X1 and X2 are hydrogen, lower alkyl or lower acyl; R1 is hydrogen or lower alkyl; R2 is hydrogen, lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, or R1 and R2 together with the carbon atom to which they are attached form a cycloalkyl or heterocyclic group; R3 is aryl; n is 0-2 are obtained from aryl haloalkyl sulfide and aryl alkyl sulfide intermediates. The hydroxamic acids have the potential of being inhibitors of matrix **metalloproteases**. In an example, 4-[4-(4-chlorophenoxy)phenylsulfonylmethyl]-4-(N-hydroxycarboxamido)tetrahydropyran was obtained starting from 4-(4-chlorophenoxy)phenylsulfonyl chloride and Et tetrahydropyran-4-carboxylate.
RE.CNT 5
(1) Creger, P; Journal of the American Chemical Society 1967, V89, P2500 CAPLUS
(2) Jeffrey, A; US 5672599 A 1997
(3) Michael, S; US 3966848 A 1976 CAPLUS
(4) Monsanto; WO 9208688 A 1992
(5) Rynbrandt, R; Tetrahedron Letters 1972, V19, P1937

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2000 ACS
AN 1999:736703 CAPLUS
DN 131:336951
TI Preparation of substituted aryl hydroxamic acids as **metalloproteinase** inhibitors
IN Xue, Chu-Biao; Decicco, Carl P.; Wexler, Ruth R.
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9958528	A1	19991118	WO 1999-US10358	19990512
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9940747	A1	19991129	AU 1999-40747	19990512

PRAI US 1998-85393 19980514
WO 1999-US10358 19990512
OS MARPAT 131:336951
GI For diagram(s), see printed CA Issue.
AB Aryl hydroxamic acids I [ring is a 5-8 membered ring contg. 0-2

heteroatoms selected from N, O, and S; Rb = F, Me; X = CH2CO, CH2CO2, CH2CONH, etc.; Y = OCH2O, CH2O, OCHMe, etc.; Z = CH, N; R1 = F, H, Cl, Et, etc.; R2 = F, Cl, Br, I, MeO, etc.; R3 = CHMe2, F, Cl, CF3, etc.; R4 = H; R3R4 form a 5-6 membered arom. ring contg. 0-2 heteroatoms; p = 0-2], which are useful as **metalloprotease** inhibitors (no data), were prepd. E.g., 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl] **sulfonyl**]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide mono(trifluoroacetate) was prepd.

RE.CNT 3

(1) Ciba Geigy AG; WO 9600214 A 1996

(2) Hoffmann La Roche; EP 0780386 A 1997

(3) McDonald, J; WO 9839315 A 1998

L11 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2000 ACS

AN 1999:464012 CAPLUS

DN 131:97624

TI MMP inhibitors for the treatment of ocular angiogenesis

IN Doherty, Niall Stephen

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 930067	A2	19990721	EP 1998-310351	19981216
	EP 930067	A3	19990915		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	AU 9897224	A1	19990708	AU 1998-97224	19981218
	JP 11263735	A2	19990928	JP 1998-360567	19981218
PRAI	US 1997-68261		19971219		

AB The present invention relates to the use of matrix **metalloproteinase** inhibitors, preferably those which display specificity for matrix **metalloproteinases**-2 or 9, in the treatment or prevention of ocular angiogenesis. Matrix **metalloproteinase** inhibitors are e.g. 3-[[4-[fluorophenoxy]benzenesulfonyl]-[1-hydroxycarbamoylcyclopentyl]amino]propionic acid and N-hydroxy-2-[4-phenylpiperidine-1-**sulfonyl**]acetamide.

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2000 ACS

AN 1999:350651 CAPLUS

DN 131:18929

TI Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix **metalloprotease** inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Boehm, Terri L.; De Crescenzo, Gary A.; Villamil, Clara I.; McDonald, Joseph J.; Freskos, John N.; Getman, Daniel P.

PA G.D. Searle & Co., USA

SO PCT Int. Appl., 840 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925687	A1	19990527	WO 1998-US23242	19981112
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,				

TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9913732 A1 19990607 AU 1999-13732 19981112
PRAI US 1997-66007 19971114 = 09/356,948
US 1997-PV66007 19971114
WO 1998-US23242 19981112
OS MARPAT 131:18929
GI



I

AB A process for treating conditions assocd. with pathol. matrix **metalloproteinase** (MMP) activity comprises administration of compds. having inhibitory activity against >1 of MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition of MMP-1. The compds. are of the form HONHCOCR1R2SO2R3 [R1, R2 = H; R1R2 = atoms to form a 5-8 membered ring contg. 1-3 heteroatoms; R3 = (substituted) aryl, heteroaryl]. Thus, 4-PhOC6H4SH was heated in Me2SO to give the disulfide dimer, which in THF was added to a mixt. of Et N-tert-butoxycarbonylisonipecotate (prepn. given) and LDA in THF at -60.degree. to room temp. to give 405 sulfide, which was oxidized with m-ClC6H4CO(OOH) to give 59% **sulfone**. The Et ester was sapond. with NaOH in EtOH/H2O to give 100% acid, which in DMF was treated with hydroxybenzotriazole, EDC, 4-methylmorpholine, and aq. NH2OH to give title compd. (I). I inhibited MMP-2 with IC50 = 0.2 nM.

RE.CNT 6
(1) American Cyanamid Co; WO 9837877 A 1998
(2) American Cyanamid Co; WO 9838163 A 1998
(3) Groneberg, R; WO 9724117 A 1997
(4) Hoffmann La Roche; EP 0780386 A 1997
(5) Takeda Chem Ind Ltd; JP 04338331 A 1992
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2000 ACS
AN 1999:169861 CAPLUS
DN 131:2122
TI Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors
AU Lovejoy, Brett; Welch, Anthony R.; Carr, Steven; Luong, Christine; Broka, Chris; Hendricks, R. Than; Campbell, Jeffery A.; Walker, Keith A. M.; Martin, Robert; Van Wart, Harold; Browner, Michelle F.
CS Inflammatory Diseases Unit, Roche Bioscience, Palo Alto, CA, 94304, USA
SO Nat. Struct. Biol. (1999), 6(3), 217-221
CODEN: NSBIEW; ISSN: 1072-8368
PB Nature America
DT Journal
LA English
AB The X-ray crystal structures of the catalytic domain of human collagenase-3 (MMP-13) and collagenase-1 (MMP-1) with bound inhibitors

provides a basis for understanding the selectivity profile of a novel series of matrix **metalloprotease** (MMP) inhibitors. Differences in the relative size and shape of the MMP S1' pockets suggest that this pocket is a crit. determinant of MMP inhibitor selectivity. The collagenase-3 S1' pocket is long and open, easily accommodating large P1' groups, such as diphenylether. In contrast, the collagenase-1 S1' pocket must undergo a conformational change to accommodate comparable P1' groups.

The selectivity of the diphenylether series of inhibitors for collagenase-3 is largely detd. by their affinity for the preformed S1' pocket of collagenase-3, as compared to the induced fit in collagenase-1.

RE.CNT 28
(2) Babine, R; Chem Rev 1997, V97, P1359 CAPLUS
(3) Bairoch, A; Nucleic Acids Res 1998, V26, P38 CAPLUS
(4) Bernstein, F; J Mol Biol 1977, V112, P535 CAPLUS
(5) Billinghurst, R; J Clin Invest 1997, V99, P1534 CAPLUS
(7) Borkakoti, N; Struct Biol 1994, V1, P106 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2000 ACS
AN 1998:498326 CAPLUS
DN 129:148991
TI Preparation of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as **metalloproteinase** inhibitors
IN Broka, Chris Allen; Campbell, Jeffrey Allen; Castelhano, Arlindo Lucas; Chen, Jian Jeffrey; Hendricks, Robert Than; Melnick, Michael Joseph; Walker, Keith Adrian Murray
PA F. Hoffmann-La Roche A.-G., Switz.; Agouron Pharmaceuticals, Inc.
SO Ger. Offen., 84 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19802350	A1	19980730	DE 1998-19802350	19980122
	WO 9832748	A1	19980730	WO 1998-EP180	19980114
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9866140	A1	19980818	AU 1998-66140	19980114
	EP 958287	A1	19991124	EP 1998-907943	19980114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	ZA 9800376	A	19980723	ZA 1998-376	19980116
	FR 2758559	A1	19980724	FR 1998-601	19980121
	US 5998412	A	19991207	US 1998-9951	19980121
	GB 2321641	A1	19980805	GB 1998-1393	19980122
	ES 2136037	A1	19991101	ES 1998-113	19980122
	NO 9903587	A	19990922	NO 1999-3587	19990722

PRAI US 1997-PV36714 19970123
US 1997-PV62209 19971016
WO 1998-EP180 19980114
OS MARPAT 129:148991
GI



II

AB R10COCR1R2NR3SO2NR20R21 [I; R1-R3 = H, (CO-interrupted) alkyl, heterocyclyl(alkyl), (hetero)aryl(alkyl), etc.; R1R2, R1R3, R2R3 = atoms to complete a ring; R10 = NR11OR12; R11,R12 = H or (ar)alkyl; R20,R21 = H, alkyl, (hetero)aryl[alk(en)yl], etc.; NR20R21heterocyclyl] were prepd. Thus, (R)-1-[4-(4-chlorobenzoyl)piperidine-1-**sulfonyl**]piperidine-2-carboxylic acid was amidated by H2NOCMe3 and the product deprotected to give title compd. (R)-II. Data for biol. activity of I were given.

L11 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2000 ACS
AN 1997:456150 CAPLUS
DN 127:162116
TI Arylsulfonamido-substituted hydroxamic acids
IN MacPherson, Lawrence J.; Parker, David T.
PA Ciba-Geigy Corp., USA
SO U.S., 31 pp. Cont.-in-part of U.S. 5,552,419.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5646167	A	19970708	US 1995-475166	19950607
	US 5455258	A	19951003	US 1993-1136	19930106
	US 5506242	A	19960409	US 1994-265296	19940624
	US 5552419	A	19960903	US 1994-333676	19941103
	WO 9640101	A1	19961219	WO 1996-EP2418	19960604
	W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9661249	A1	19961230	AU 1996-61249	19960604
	US 5817822	A	19981006	US 1997-787730	19970124

PRAI US 1993-1136 19930106
US 1994-265296 19940624
US 1994-333676 19941103
NZ 1993-250517 19931220
US 1995-475166 19950607
WO 1996-EP2418 19960604

OS MARPAT 127:162116
AB Arylsulfonamido-substituted hydroxamic acids HONHCOCR1R2N(CH2R)SO2Ar (Ar = carbocyclic or heterocyclic aryl; R, R1 = H, alkyl, aryl, etc.; R2 = H, alkyl; R and R1 or R1 and R2 may form a ring) or their pharmaceutically acceptable prodrug derivs. or salts were prepd. as antitumor agents. Thus, N-hydroxy-2(R)-[(4-methoxybenzenesulfonyl)(3-picolyl)amino]-3-methylbutanamide was prepd. from D-valine, 4-methoxybenzenesulfonyl chloride, 3-picolyl chloride hydrochloride, and O-tert-butylhydroxylamine hydrochloride.

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2000 ACS
AN 1996:275067 CAPLUS
DN 125:34156
TI Arylsulfonamido-substituted hydroxamic acids and method of inhibiting **metalloelastase** activity, inhibiting elastin degradation, or treating macrophage **metalloelastase** dependent conditions in mammals
IN MacPherson, Lawrence J.; Parker, David T.; Jeng, Arco Y.
PA Ciba-Geigy Corp., USA
SO U.S., 32 pp. Cont.-in-part of U.S. 5,455,258.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5506242	A	19960409	US 1994-265296	19940624
	US 5455258	A	19951003	US 1993-1136	19930106
	US 5552419	A	19960903	US 1994-333676	19941103
	US 5646167	A	19970708	US 1995-475166	19950607
	WO 9600214	A1	19960104	WO 1995-IB464	19950612
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2192092	AA	19960104	CA 1995-2192092	19950612
	AU 9525369	A1	19960119	AU 1995-25369	19950612
	AU 692553	B2	19980611		
	EP 766672	A1	19970409	EP 1995-919600	19950612
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	HU 76548	A2	19970929	HU 1996-3592	19950612
	JP 11505502	T2	19990521	JP 1995-502968	19950612
	ZA 9505206	A	19951227	ZA 1995-5206	19950623
	US 5672615	A	19970930	US 1996-613303	19960311
	FI 9605156	A	19961220	FI 1996-5156	19961220
	NO 9605568	A	19970217	NO 1996-5568	19961223
	US 5817822	A	19981006	US 1997-787730	19970124

PRAI US 1993-1136 19930106
NZ 1993-250517 19931220
US 1994-265296 19940624
US 1994-333676 19941103
US 1995-475166 19950607
WO 1995-IB464 19950612
OS MARPAT 125:34156
GI



I

AB The invention relates to a method of inhibiting **metalloelastase** activity, of inhibiting the degrdn. of elastin, or of treating macrophage

metalloelastase dependent conditions in mammals which comprises administering to a mammal in need thereof an effective macrophage **metalloelastase** inhibiting amt. of (HO)NHCOCR1R2N(CH2R)SO2Ar wherein: Ar is carbocyclic or heterocyclic aryl; R is, e.g., H, lower alkyl, carbocyclic aryl-lower alkyl; R1 is, e.g., H, lower alkyl, carbocyclic aryl-lower alkyl; R2 = H or lower alkyl, or of a pharmaceutically acceptable prodrug deriv. thereof, or of a pharmaceutically acceptable salt thereof, or of pharmaceutical compns. comprising a said compd. Thus, e.g., treatment of D-valine with 4-methoxybenzenesulfonyl chloride followed by esterification with N,N-dimethylformamide di-t-Bu acetal afforded N-[4-methoxybenzenesulfonyl]-D-valine t-Bu ester; treatment of the latter with 3-picolyl chloride hydrochloride followed by HCl afforded 2(R)-[[4-methoxybenzenesulfonyl](3-picolyl)amino]-3-methylbutanoic acid hydrochloride; coupling with O-t-butylhydroxylamine hydrochloride followed by HCl afforded N-hydroxy-2(R)-[[4-methoxybenzenesulfonyl](3-picolyl)amino]-3-methylbutanamide.xHCl (I.xHCl) which inhibited stromelysin (based on its hydrolysis of Substance P) with Ki = 17 nM, inhibited stromelysin (based on human aggrecan substrate) with IC50 = 55 nM, inhibited collagenase with Ki = 62 nM, and inhibited the degrdn. of [3H]elastin by mouse macrophage **metalloelastase** with an IC50 of about 8 nM. Pharmaceutical formulations were given.

=> d hitstr 6

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2000 ACS
IT **193022-38-7D**, RS 104966, complexes with collagenase-1
RL: PRP (Properties)
(RS 104966; crystal structures of human MMP-1 and -13 and differences in the size and shape of S1' pockets of the collagenases)
RN 193022-38-7 CAPLUS
CN 2H-Pyran-4-acetamide, tetrahydro-N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-(9CI) (CA INDEX NAME)



IT **193022-04-7D**, RS 130830, complexes with collagenase-3
RL: PRP (Properties)
(RS 130830; crystal structures of human MMP-1 and -13 and differences in the size and shape of S1' pockets of the collagenases)
RN 193022-04-7 CAPLUS
CN 2H-Pyran-4-carboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



IT **193022-21-8D**, RS 113456, complexes with collagenase-3
RL: PRP (Properties)
(crystal structures of human MMP-1 and -13 and differences in the size and shape of S1' pockets of the collagenases)
RN 193022-21-8 CAPLUS
CN 2H-Pyran-4-acetamide,
4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)


Cl
O
S
O
O
O
CH2
C
NH
OH
O

d hitstr 7

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2000 ACS
IT **210916-20-4P 210916-24-8P 210916-25-9P**
210916-27-1P 210916-28-2P 210916-34-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as **metalloproteinase** inhibitors)
RN 210916-20-4 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]amino]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 210916-24-8 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 210916-25-9 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[[4-(5-chloro-2-pyridinyl)-1-piperazinyl]sulfonyl]amino]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



L11 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2000 ACS
IT **161314-03-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylsulfonamido-substituted hydroxamic acids as matrix-degrading **metalloproteinase** inhibitors)
RN 161314-03-0 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[(4-methoxyphenyl)sulfonyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



=> d hitstr 9

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2000 ACS
IT **161314-03-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(arylsulfonamido-substituted hydroxamic acids and method of inhibiting **metalloelastase** activity, inhibiting elastin degrdn., or treating macrophage **metalloelastase** dependent conditions in mammals)
RN 161314-03-0 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[(4-methoxyphenyl)sulfonyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L10 HAS NO ANSWERS
L10 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

=> s l10 ful

FULL SEARCH INITIATED 08:54:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 617 TO ITERATE

100.0% PROCESSED 617 ITERATIONS 513 ANSWERS
SEARCH TIME: 00.00.01

L12 513 SEA SSS FUL L10

=> s l12

L14 3 L12

=> d bib abs 1-3

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1999:468334 CAPLUS
DN 131:125454
TI Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases
IN McClure, Kim Francis; Lopresti-Morrow, Lori Lynn; Mitchell, Peter Geoffrey; Reeves, Lisa Marie; Reiter, Lawrence Alan; Robinson, Ralph Pelton; Yocum, Sue Ann
PA Pfizer Products Inc., USA
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11199512	A2	19990727	JP 1998-289540	19981012
	EP 935963	A2	19990818	EP 1998-308563	19981020
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2251197	AA	19990424	CA 1998-2251197	19981022
	AU 9889481	A1	19990520	AU 1998-89481	19981022
PRAI	US 1997-62766		19971024		

AB Matrix metalloprotease (MMP)-13 selective inhibitors including 1-{[4-(4-fluorophenoxy)benzenesulfonyl]-pyridin-3-ylmethylamino}-cyclopentanecarboxylic acid and other compds. and their pharmaceutically acceptable salts are claimed for treatment of arthritis deformans and other MMP-related diseases. The inhibitory effects of these compds. on MMP 1 and MMP 13 were tested.

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1999:388166 CAPLUS
DN 131:44740
TI Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors.
IN Dack, Kevin Neil; Whitlock, Gavin Alistair
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929667	A1	19990617	WO 1998-EP6640	19981009
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,				

TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9912301 A1 19990628 AU 1999-12301 19981009
PRAI GB 1997-25782 19971205
WO 1998-EP6640 19981009
OS MARPAT 131:44740
GI



I

AB Title compds. [I; dotted line = optional double bond; A = C, CH; B = CH2, O, null; R1, R2 = H, (substituted) alkyl, alkenyl; R1R2C = (benzo-fused) C3-6 cycloalkyl group optionally incorporating O, SO, SO2, NR6; R3 = H, halo, R7, OR7; R4 = H, alkyl, alkoxy, CF3, halo; R6 = H, alkyl; R7 = (substituted) mono- or bicyclic ring system; m = 1, 2; n = 0-2; with the proviso that B is not O when A is C], were prepd. as MMP inhibitors useful in the treatment of tissue ulceration, wound repair and skin diseases. Thus, Me 2-[4-(3-methyl-4-phenylphenyl)-1,2,3,6-tetrahydropyridin-1-ylsulfonyl]acetate (prepn. given) was refluxed with NH2OH.HCl and K2CO3 in THF/MeOH to give N-hydroxy-2-[4-(3-methyl-4-phenylphenyl)-1,2,3,6-tetrahydropyridin-1-ylsulfonyl]acetamide. The latter inhibited matrix metalloproteinase 3 with IC50 = 16 nM.
RE.CNT 2
(1) Ciba Geigy AG; EP 0606046 A 1994
(2) Hoffmann La Roche; EP 0780386 A 1997

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1999:350651 CAPLUS
DN 131:18929
TI Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors
IN Barta, Thomas E.; Becker, Daniel P.; Boehm, Terri L.; De Crescenzo, Gary A.; Villamil, Clara I.; McDonald, Joseph J.; Freskos, John N.; Getman, Daniel P.
PA G.D. Searle & Co., USA
SO PCT Int. Appl., 840 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9925687	A1	19990527	WO 1998-US23242	19981112

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,

TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9913732 A1 19990607 AU 1999-13732 19981112
PRAI US 1997-66007 19971114
US 1997-PV66007 19971114
WO 1998-US23242 19981112
OS MARPAT 131:18929
GI



I

AB A process for treating conditions assocd. with pathol. matrix metalloproteinase (MMP) activity comprises administration of compds. having inhibitory activity against >1 of MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition of MMP-1. The compds. are of the form HONHCOCR1R2SO2R3 [R1, R2 = H; R1R2 = atoms to form a 5-8 membered ring contg. 1-3 heteroatoms; R3 = (substituted) aryl, heteroaryl]. Thus, 4-PhOC6H4SH was heated in Me2SO to give the disulfide dimer, which in THF was added to a mixt. of Et N-tert-butoxycarbonylisonipecotate (prepn. given) and LDA in THF at -60.degree. to room temp. to give 405 sulfide, which was oxidized with m-ClC6H4CO(OOH) to give 59% sulfone. The Et ester was sapond. with NaOH in EtOH/H2O to give 100% acid, which in DMF was treated with hydroxybenzotriazole, EDC, 4-methylmorpholine, and aq. NH2OH to give title compd. (I). I inhibited MMP-2 with IC50 = 0.2 nM.

RE.CNT 6
(1) American Cyanamid Co; WO 9837877 A 1998
(2) American Cyanamid Co; WO 9838163 A 1998
(3) Groneberg, R; WO 9724117 A 1997
(4) Hoffmann La Roche; EP 0780386 A 1997
(5) Takeda Chem Ind Ltd; JP 04338331 A 1992
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1999:468334 CAPLUS
DN 131:125454
TI Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases
IN McClure, Kim Francis; Lopresti-Morrow, Lori Lynn; Mitchell, Peter Geoffrey; Reeves, Lisa Marie; Reiter, Lawrence Alan; Robinson, Ralph Pelton; Yocum, Sue Ann
PA Pfizer Products Inc., USA
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11199512	A2	19990727	JP 1998-289540	19981012
EP 935963	A2	19990818	EP 1998-308563	19981020
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2251197	AA	19990424	CA 1998-2251197	19981022
AU 9889481	A1	19990520	AU 1998-89481	19981022

PRAI US 1997-62766 19971024
AB Matrix metalloprotease (MMP)-13 selective inhibitors including 1-{[4-(4-fluorophenoxy)benzenesulfonyl]-pyridin-3-ylmethylamino}-cyclopentanecarboxylic acid and other compds. and their pharmaceutically acceptable salts are claimed for treatment of arthritis deformans and other MMP-related diseases. The inhibitory effects of these compds. on MMP 1 and MMP 13 were tested.
IT **226389-91-9**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases)
RN 226389-91-9 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



```
=> s wo9837877/pn

L1             1 WO9837877/PN

=> select l1

ENTER ANSWER NUMBER OR RANGE (1-):1

ENTER DISPLAY CODE (TI) OR ?:rn

E1 THROUGH E634 ASSIGNED

=> fil reg

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     1.76       1.91

FILE 'REGISTRY' ENTERED AT 09:58:39 ON 08 MAR 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:    7 MAR 2000  HIGHEST RN 258356-66-0
DICTIONARY FILE UPDATES:   7 MAR 2000  HIGHEST RN 258356-66-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 13, 1999

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Structure search limits have been increased.  See HELP SLIMIT
for details.

=> s e450-e634

             1 212770-29-1/BI
               (212770-29-1/RN)
             1 212770-30-4/BI
               (212770-30-4/RN)
             1 212770-31-5/BI
               (212770-31-5/RN)
             1 212770-32-6/BI
               (212770-32-6/RN)
             1 212770-33-7/BI
               (212770-33-7/RN)
             1 212770-34-8/BI
               (212770-34-8/RN)
             1 212770-35-9/BI
               (212770-35-9/RN)
             1 212770-36-0/BI
               (212770-36-0/RN)
             1 212770-37-1/BI
               (212770-37-1/RN)
             1 212770-38-2/BI
               (212770-38-2/RN)
             1 212770-39-3/BI
```

(212770-39-3/RN)
1 212770-40-6/BI
(212770-40-6/RN)
1 212770-41-7/BI
(212770-41-7/RN)
1 212770-42-8/BI
(212770-42-8/RN)
1 212770-43-9/BI
(212770-43-9/RN)
1 212770-44-0/BI
(212770-44-0/RN)
1 212770-45-1/BI
(212770-45-1/RN)
1 212770-46-2/BI
(212770-46-2/RN)
1 212770-47-3/BI
(212770-47-3/RN)
1 212770-48-4/BI
(212770-48-4/RN)
1 212770-49-5/BI
(212770-49-5/RN)
1 212770-50-8/BI
(212770-50-8/RN)
1 212770-51-9/BI
(212770-51-9/RN)
1 212770-52-0/BI
(212770-52-0/RN)
1 212770-53-1/BI
(212770-53-1/RN)
1 212770-54-2/BI
(212770-54-2/RN)
1 212770-55-3/BI
(212770-55-3/RN)
1 212770-56-4/BI
(212770-56-4/RN)
1 212770-58-6/BI
(212770-58-6/RN)
1 212770-59-7/BI
(212770-59-7/RN)
1 212770-61-1/BI
(212770-61-1/RN)
1 212770-62-2/BI
(212770-62-2/RN)
1 212770-63-3/BI
(212770-63-3/RN)
1 212770-64-4/BI
(212770-64-4/RN)
1 212770-65-5/BI
(212770-65-5/RN)
1 212770-66-6/BI
(212770-66-6/RN)
1 212770-67-7/BI
(212770-67-7/RN)
1 212770-68-8/BI
(212770-68-8/RN)
1 212770-69-9/BI
(212770-69-9/RN)
1 212770-70-2/BI
(212770-70-2/RN)
1 212770-71-3/BI
(212770-71-3/RN)
1 212770-72-4/BI
(212770-72-4/RN)
1 212770-73-5/BI
(212770-73-5/RN)

1 212770-74-6/BI
(212770-74-6/RN)
1 212770-75-7/BI
(212770-75-7/RN)
1 212770-76-8/BI
(212770-76-8/RN)
1 212770-77-9/BI
(212770-77-9/RN)
1 212770-78-0/BI
(212770-78-0/RN)
1 212770-79-1/BI
(212770-79-1/RN)
1 212770-80-4/BI
(212770-80-4/RN)
1 212770-81-5/BI
(212770-81-5/RN)
1 212770-83-7/BI
(212770-83-7/RN)
1 212770-84-8/BI
(212770-84-8/RN)
1 212770-86-0/BI
(212770-86-0/RN)
1 212770-87-1/BI
(212770-87-1/RN)
1 212770-88-2/BI
(212770-88-2/RN)
1 212770-89-3/BI
(212770-89-3/RN)
1 212770-90-6/BI
(212770-90-6/RN)
1 212770-91-7/BI
(212770-91-7/RN)
1 212770-92-8/BI
(212770-92-8/RN)
1 212770-93-9/BI
(212770-93-9/RN)
1 212770-94-0/BI
(212770-94-0/RN)
1 212770-95-1/BI
(212770-95-1/RN)
1 212770-96-2/BI
(212770-96-2/RN)
1 212770-97-3/BI
(212770-97-3/RN)
1 212770-98-4/BI
(212770-98-4/RN)
1 212770-99-5/BI
(212770-99-5/RN)
1 212771-00-1/BI
(212771-00-1/RN)
1 212771-01-2/BI
(212771-01-2/RN)
1 212771-02-3/BI
(212771-02-3/RN)
1 212771-03-4/BI
(212771-03-4/RN)
1 212771-04-5/BI
(212771-04-5/RN)
1 212771-05-6/BI
(212771-05-6/RN)
1 212771-06-7/BI
(212771-06-7/RN)
1 212771-08-9/BI
(212771-08-9/RN)
1 212771-09-0/BI

(212771-09-0/RN)
1 212771-10-3/BI
(212771-10-3/RN)
1 212771-11-4/BI
(212771-11-4/RN)
1 212771-12-5/BI
(212771-12-5/RN)
1 212771-13-6/BI
(212771-13-6/RN)
1 212771-14-7/BI
(212771-14-7/RN)
1 212771-15-8/BI
(212771-15-8/RN)
1 212771-16-9/BI
(212771-16-9/RN)
1 212771-17-0/BI
(212771-17-0/RN)
1 212771-18-1/BI
(212771-18-1/RN)
1 212771-19-2/BI
(212771-19-2/RN)
1 212771-20-5/BI
(212771-20-5/RN)
1 212771-21-6/BI
(212771-21-6/RN)
1 212771-22-7/BI
(212771-22-7/RN)
1 212771-23-8/BI
(212771-23-8/RN)
1 212771-24-9/BI
(212771-24-9/RN)
1 212771-25-0/BI
(212771-25-0/RN)
1 212771-26-1/BI
(212771-26-1/RN)
1 212771-27-2/BI
(212771-27-2/RN)
1 212771-29-4/BI
(212771-29-4/RN)
1 212771-30-7/BI
(212771-30-7/RN)
1 212771-31-8/BI
(212771-31-8/RN)
1 212771-32-9/BI
(212771-32-9/RN)
1 212771-33-0/BI
(212771-33-0/RN)
1 212771-34-1/BI
(212771-34-1/RN)
1 212771-35-2/BI
(212771-35-2/RN)
1 212771-36-3/BI
(212771-36-3/RN)
1 212771-37-4/BI
(212771-37-4/RN)
1 212771-38-5/BI
(212771-38-5/RN)
1 212771-39-6/BI
(212771-39-6/RN)
1 212771-40-9/BI
(212771-40-9/RN)
1 212771-41-0/BI
(212771-41-0/RN)
1 212771-42-1/BI
(212771-42-1/RN)

1 212771-43-2/BI
(212771-43-2/RN)
1 212771-44-3/BI
(212771-44-3/RN)
1 212771-45-4/BI
(212771-45-4/RN)
1 212771-46-5/BI
(212771-46-5/RN)
1 212771-47-6/BI
(212771-47-6/RN)
1 212771-48-7/BI
(212771-48-7/RN)
1 212772-29-7/BI
(212772-29-7/RN)
1 2160-93-2/BI
(2160-93-2/RN)
1 22999-69-5/BI
(22999-69-5/RN)
1 2365-48-2/BI
(2365-48-2/RN)
1 2550-36-9/BI
(2550-36-9/RN)
1 2557-77-9/BI
(2557-77-9/RN)
1 2623-95-2/BI
(2623-95-2/RN)
1 2743-05-7/BI
(2743-05-7/RN)
1 2743-06-8/BI
(2743-06-8/RN)
1 2850-19-3/BI
(2850-19-3/RN)
1 2850-21-7/BI
(2850-21-7/RN)
1 28743-98-8/BI
(28743-98-8/RN)
1 2882-19-1/BI
(2882-19-1/RN)
1 30389-85-6/BI
(30389-85-6/RN)
1 30512-68-6/BI
(30512-68-6/RN)
1 30749-64-5/BI
(30749-64-5/RN)
1 3099-31-8/BI
(3099-31-8/RN)
1 3172-52-9/BI
(3172-52-9/RN)
1 3355-28-0/BI
(3355-28-0/RN)
1 3433-80-5/BI
(3433-80-5/RN)
1 371-42-6/BI
(371-42-6/RN)
1 4142-04-5/BI
(4142-04-5/RN)
1 42520-97-8/BI
(42520-97-8/RN)
1 4261-60-3/BI
(4261-60-3/RN)
1 4261-68-1/BI
(4261-68-1/RN)
1 42990-70-5/BI
(42990-70-5/RN)
1 4392-24-9/BI

(4392-24-9/RN)
1 51-75-2/BI
(51-75-2/RN)
1 5292-43-3/BI
(5292-43-3/RN)
1 533-68-6/BI
(533-68-6/RN)
1 5333-88-0/BI
(5333-88-0/RN)
1 535-11-5/BI
(535-11-5/RN)
1 538-07-8/BI
(538-07-8/RN)
1 5394-18-3/BI
(5394-18-3/RN)
1 5445-29-4/BI
(5445-29-4/RN)
1 55-51-6/BI
(55-51-6/RN)
1 565-74-2/BI
(565-74-2/RN)
1 588-63-6/BI
(588-63-6/RN)
1 589-15-1/BI
(589-15-1/RN)
1 598-72-1/BI
(598-72-1/RN)
1 60-56-0/BI
(60-56-0/RN)
1 60876-94-0/BI
(60876-94-0/RN)
1 609-12-1/BI
(609-12-1/RN)
1 6138-90-5/BI
(6138-90-5/RN)
1 615-83-8/BI
(615-83-8/RN)
1 615-96-3/BI
(615-96-3/RN)
1 619-34-1/BI
(619-34-1/RN)
1 622-86-6/BI
(622-86-6/RN)
1 6258-60-2/BI
(6258-60-2/RN)
1 6320-02-1/BI
(6320-02-1/RN)
1 637-59-2/BI
(637-59-2/RN)
1 637-89-8/BI
(637-89-8/RN)
1 65251-07-2/BI
(65251-07-2/RN)
1 6959-48-4/BI
(6959-48-4/RN)
1 696-63-9/BI
(696-63-9/RN)
1 78-77-3/BI
(78-77-3/RN)
1 80-58-0/BI
(80-58-0/RN)
1 824-94-2/BI
(824-94-2/RN)
1 824-98-6/BI
(824-98-6/RN)

1 86288-08-6/BI
(86288-08-6/RN)
1 870-63-3/BI
(870-63-3/RN)
1 9001-12-1/BI
(9001-12-1/RN)
1 91-60-1/BI
(91-60-1/RN)
1 91554-08-4/BI
(91554-08-4/RN)
1 91554-59-5/BI
(91554-59-5/RN)
1 91561-99-8/BI
(91561-99-8/RN)
1 92549-40-1/BI
(92549-40-1/RN)
1 92645-52-8/BI
(92645-52-8/RN)
1 92902-76-6/BI
(92902-76-6/RN)
1 939-26-4/BI
(939-26-4/RN)
1 98-09-9/BI
(98-09-9/RN)

L2 185 (212770-29-1/BI OR 212770-30-4/BI OR 212770-31-5/BI OR 212770-32
-6/BI OR 212770-33-7/BI OR 212770-34-8/BI OR 212770-35-9/BI OR
212770-36-0/BI OR 212770-37-1/BI OR 212770-38-2/BI OR 212770-39-
3/BI OR 212770-40-6/BI OR 212770-41-7/BI OR 212770-42-8/BI OR
212770-43-9/BI OR 212770-44-0/BI OR 212770-45-1/BI OR 212770-46-
2/BI OR 212770-47-3/BI OR 212770-48-4/BI OR 212770-49-5/BI OR
212770-50-8/BI OR 212770-51-9/BI OR 212770-52-0/BI OR 212770-53-
1/BI OR 212770-54-2/BI OR 212770-55-3/BI OR 212770-56-4/BI OR
212770-58-6/BI OR 212770-59-7/BI OR 212770-61-1/BI OR 212770-62-
2/BI OR 212770-63-3/BI OR 212770-64-4/BI OR 212770-65-5/BI OR
212770-66-6/BI OR 212770-67-7/BI OR 212770-68-8/BI OR 212770-69-
9/BI OR 212770-70-2/BI OR 212770-71-3/BI OR 212770-72-4/BI OR
212770-73-5/BI OR 212770-74-6/BI OR 212770-75-7/BI OR 212770-76-
8/BI OR 212770-77-9/BI OR 212770-78-0/BI OR 212770-79-1/BI OR
212770-80-4/BI OR 212770-81-5/BI OR 212770-83-7/BI OR 212770-84-
8/BI OR 212770-86-0/BI OR 212770-87-1/BI O

=> d scan

L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 4-[(4-butoxyphenyl)sulfonyl]-1-(2-phenoxyethyl)- (9CI)
MF C24 H31 N O6 S



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):24

L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 1-cyclooctyl-4-[(4-methoxyphenyl)sulfonyl]-
(9CI)
MF C21 H31 N O5 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Benzenepropanoic acid,
.alpha.-[(4-methoxyphenyl)sulfonyl]-.alpha.-methyl-
4-[2-(4-morpholinyl)ethoxy]-, ethyl ester (9CI)
MF C25 H33 N O7 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[(4-bromophenyl)thio]-, ethyl ester (9CI)
MF C11 H13 Br O2 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Decanoic acid, 2-bromo- (7CI, 8CI, 9CI)
MF C10 H19 Br O2
CI COM



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Ethanamine, 2-chloro-N-(2-chloroethyl)-N-methyl- (9CI)
MF C5 H11 Cl2 N
CI COM



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 4-[(4-butoxyphenyl)sulfonyl]-1-(2-phenoxyethyl)-, ethyl ester (9CI)
MF C26 H35 N O6 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 1-cyclooctyl-4-[(4-methoxyphenyl)sulfonyl]-, ethyl ester (9CI)
MF C23 H35 N O5 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Heptanoic acid, 2-[(4-methoxyphenyl)thio]- (9CI)
MF C14 H20 O3 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS

IN Ethanol, 2,2'-[[(3,4-dichlorophenyl)methyl]imino]bis- (9CI)
MF C11 H15 Cl2 N O2



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Benzenethiol, 3-fluoro- (9CI)
MF C6 H5 F S
CI COM



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Benzenepropanamide, 4-[2-(diethylamino)ethoxy]-.alpha.-[[4-(2-furanyl)phenyl]sulfonyl]-N-hydroxy-.alpha.-methyl-, monohydrochloride (9CI)
MF C26 H32 N2 O6 S . Cl H



● HCl

L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)sulfonyl]-1-(2-phenoxyethyl)- (9CI)
MF C21 H25 N O6 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 1-butyl-4-[(4-methoxyphenyl)sulfonyl]- (9CI)
MF C17 H25 N O5 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Heptanoic acid, 2-[(4-methoxyphenyl)thio]-, ethyl ester (9CI)
MF C16 H24 O3 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-bromo-3-(phenylmethoxy)- (9CI)
MF C10 H11 Br O3



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Cyclohexane, (bromomethyl)- (6CI, 7CI, 8CI, 9CI)
MF C7 H13 Br
CI COM



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanamide, N-hydroxy-2-[(3-methylbutyl)sulfinyl]- (9CI)
MF C8 H17 N O3 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 4-[(4-methoxyphenyl)sulfonyl]-1-(2-phenoxyethyl)-, ethyl ester (9CI)
MF C23 H29 N O6 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 1-butyl-4-[(4-methoxyphenyl)sulfonyl]-, ethyl
ester (9CI)
MF C19 H29 N O5 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Hexenoic acid, 2-[(4-methoxyphenyl)sulfonyl]-5-methyl-2-(3-methyl-2-butenyl)- (9CI)
MF C19 H26 O5 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 1-Butanamine, N,N-bis(2-chloroethyl)- (9CI)
MF C8 H17 Cl2 N
CI COM



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Acetic acid, mercapto-, methyl ester (6CI, 7CI, 8CI, 9CI)
MF C3 H6 O2 S
CI COM



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanamide, N-hydroxy-2-[(4-methoxyphenyl)sulfinyl]- (9CI)
MF C10 H13 N O4 S



L2 185 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Piperidinecarboxylic acid, 4-[(4-butoxyphenyl)sulfonyl]-1-(3-phenoxypropyl)- (9CI)
MF C25 H33 N O6 S



L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1999:388166 CAPLUS
DN 131:44740
TI Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors.
IN Dack, Kevin Neil; Whitlock, Gavin Alistair
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929667	A1	19990617	WO 1998-EP6640	19981009
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1997-25782	19971205
	AU 9912301	A1	19990628	AU 1999-12301	19981009
				GB 1997-25782	19971205
				WO 1998-EP6640	19981009

OS MARPAT 131:44740
RE.CNT 2
(1) Ciba Geigy AG; EP 0606046 A 1994
(2) Hoffmann La Roche; EP 0780386 A 1997

=> d hitstr l14 2

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2000 ACS
IT **227304-22-5P 227304-23-6P 227304-26-9P**
227304-27-0P 227304-35-0P 227304-36-1P
227304-51-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-hydroxytetrahydropyridylsulfonylacetamides and related compds. as matrix metalloprotease inhibitors)
RN 227304-22-5 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[3,6-dihydro-4-(3'-methoxy-2-methyl[1,1'-biphenyl]-4-yl)-1(2H)-pyridinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 227304-23-6 CAPLUS
CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(3'-methoxy-2-methyl[1,1'-biphenyl]-4-yl)-1-piperidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2000 ACS
AN 1999:468334 CAPLUS
DN 131:125454
TI Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases
IN McClure, Kim Francis; Lopresti-Morrow, Lori Lynn; Mitchell, Peter Geoffrey; Reeves, Lisa Marie; Reiter, Lawrence Alan; Robinson, Ralph Pelton; Yocum, Sue Ann
PA Pfizer Products Inc., USA
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11199512	A2	19990727	JP 1998-289540	19981012
	EP 935963	A2	19990818	EP 1998-308563	19981020
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2251197	AA	19990424	CA 1998-2251197	19981022
	AU 9889481	A1	19990520	AU 1998-89481	19981022
PRAI	US 1997-62766		19971024		

AB Matrix metalloprotease (MMP)-13 selective inhibitors including 1-{[4-(4-fluorophenoxy)benzenesulfonyl]-pyridin-3-ylmethylamino}-cyclopentanecarboxylic acid and other compds. and their pharmaceutically acceptable salts are claimed for treatment of arthritis deformans and other MMP-related diseases. The inhibitory effects of these compds. on MMP 1 and MMP 13 were tested.
IT **226389-91-9**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases)
RN 226389-91-9 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)